By Dr. Pamela Frank, BSc(Hons), ND – Published July 2026
If there is one supplement that comes up in nearly every fertility conversation I have with patients over 35 – or with any woman told she has diminished ovarian reserve, poor egg quality, or a history of poor IVF response – it is CoQ10.
The interest is warranted. Coenzyme Q10 is one of the most-studied nutritional interventions in reproductive medicine, and its mechanistic rationale is grounded in well-established mitochondrial biology rather than speculation. But the way it is frequently discussed online conflates different forms, doses, and levels of evidence in ways that matter clinically. This post covers what CoQ10 actually does, what the research shows, who it is most likely to help, how to take it correctly, and what it cannot do.
What CoQ10 Is and Why It Matters for Egg Quality
Coenzyme Q10 – also called ubiquinone or, in its reduced active form, ubiquinol – is a fat-soluble compound found in virtually every cell in your body. Its primary role is as a cofactor in the mitochondrial electron transport chain: it shuttles electrons between complexes I/II and III, enabling ATP production through oxidative phosphorylation. Without CoQ10, mitochondria cannot efficiently produce the energy that drives cellular function.
It is also a direct antioxidant – one of the few antioxidants that is synthesized endogenously and functions within the mitochondrial membrane itself, where it protects mitochondrial DNA and membrane lipids from oxidative damage generated as a byproduct of energy production.
Both of these roles – energy production and antioxidant defence – are directly relevant to egg quality, and for the same reason: the oocyte is extraordinarily mitochondria-dependent.
Why Oocytes Are Uniquely Dependent on Mitochondrial Function
Human eggs contain approximately 100,000–200,000 mitochondria – more than virtually any other cell in the body.1 This is not incidental. The processes that determine egg quality are among the most energy-intensive in human biology:
Meiotic spindle assembly and chromosome segregation:
During maturation, the oocyte must complete two rounds of meiotic division, assembling and disassembling the meiotic spindle to distribute chromosomes correctly into the egg and polar bodies. This process requires precise, sustained ATP production. When mitochondrial energy output is insufficient, spindle assembly errors occur, resulting in chromosomal abnormalities in the egg. Aneuploid eggs either fail to fertilize, arrest in early embryo development, or result in miscarriage. This is the primary mechanism linking mitochondrial dysfunction to age-related decline in egg quality and the rise in chromosomal abnormalities seen in eggs from older women.2
Fertilization and early embryo cleavage:
After fertilization, the early embryo – before it can activate its own genome – relies entirely on maternal mitochondria for energy. The embryonic genome doesn’t begin substantial transcription until the 4–8 cell stage in humans. Everything before that runs on the mitochondrial capacity inherited from the egg.
Oocyte growth during folliculogenesis:
The 90-day maturation process, during which a primordial follicle is recruited and grows into a preovulatory follicle, is metabolically demanding. The granulosa cells surrounding the developing oocyte supply it with substrates and energy support throughout this process, but the oocyte mitochondria must function adequately to utilize these supplies.
Coenzyme Q10 levels in oocytes decline with age – in parallel with the age-related decline in egg quality. CoQ10 has been confirmed to be present in human follicular fluid, with significantly higher levels in mature oocytes versus dysmorphic oocytes, and CoQ10 in follicular fluid is positively correlated with oocyte quality. This relationship between CoQ10 availability and oocyte quality is the mechanistic foundation for supplementation. nih
The Toronto Study That Changed the Conversation
The most important piece of Coenzyme Q10 and egg quality research was conducted in Toronto – at Mount Sinai Hospital and TCART Fertility Partners – and published in 2015 in the journal Aging Cell.
Ben-Meir et al. showed that aging of the female germ line is accompanied by mitochondrial dysfunction, characterized by decreased oxidative phosphorylation and reduced ATP levels. Diminished expression of the enzymes responsible for CoQ10 production was observed in oocytes of older females in both mice and humans. The age-related decline in oocyte quality and quantity could be reversed by CoQ10 administration. nih
The researchers went further: oocyte-specific disruption of the CoQ-producing enzyme recapitulated many of the mitochondrial and reproductive phenotypes observed in older females, including reduced ATP production and increased meiotic spindle abnormalities, resulting in infertility. Premature ovarian failure in these animals could be prevented by maternal dietary administration of CoQ10. nih
This is mechanistically significant. It demonstrates that Coenzyme Q10 deficiency alone – independent of other age-related changes – is sufficient to produce the reproductive phenotype of ovarian aging, and that CoQ10 supplementation can reverse it in animal models. The Toronto fertility community has been incorporating this research into clinical practice since its publication; it is one reason CoQ10 has moved from a fringe supplement to a standard-of-care recommendation at many Ontario fertility clinics.
What the Human Clinical Trials Show
IVF Outcomes in Women with Diminished Ovarian Reserve
A prospective randomized controlled trial published in 2018 included 186 women with poor ovarian reserve stratified according to the POSEIDON classification (age under 35, poor ovarian reserve parameters). Participants were randomized to CoQ10 pretreatment for 60 days before their IVF-ICSI cycle or no pretreatment. The primary outcome was the number of high-quality embryos. nih
The CoQ10 group showed statistically significant improvements in the number of oocytes retrieved, the number of mature (MII) oocytes, the fertilization rate, the number of high-quality embryos, and the clinical pregnancy rate compared with controls who received no pretreatment. This is a well-designed RCT in the specific population most likely to benefit – young women with poor ovarian reserve – and it remains one of the strongest pieces of direct clinical evidence for CoQ10 in reproductive medicine.
Follicular Fluid CoQ10 and Oocyte Quality
Oral supplementation with CoQ10 increased CoQ10 content in follicular fluid, and follicular fluid CoQ10 was positively correlated with oocyte quality. Pretreatment with CoQ10 significantly increased the number of retrieved oocytes, fertilization rate, and number of high-quality embryos in women with poor ovarian response during IVF-ICSI cycles. nih
This matters because it closes a critical mechanistic loop: oral supplementation actually raises CoQ10 levels inside the follicle surrounding the developing egg. It is not just systemic supplementation with uncertain tissue delivery – it demonstrably reaches the follicular microenvironment where it is needed.
Ovarian Reserve Protection
A randomized, double-blind, placebo-controlled trial found that Coenzyme Q10 pretreatment at 300 mg/day for 14 days before surgery significantly attenuated the post-surgical decline in AMH compared with placebo, suggesting a protective effect on ovarian reserve under oxidative stress. While this was a surgical context, the finding supports the broader principle that CoQ10 protects ovarian tissue from oxidative damage. nih
CoQ10, PCOS and Oocyte Quality
Coenzyme Q10 has been shown to improve oocyte quality in IVF in women with PCOS, where follicular oxidative stress is significantly elevated relative to fertile controls. Women with PCOS may retrieve many eggs but have a higher proportion of immature or poor-quality oocytes – a pattern that reflects follicular oxidative stress rather than inadequate follicle number. CoQ10’s antioxidant effects in follicular fluid are directly relevant to this mechanism. nih
CoQ10 and Male Fertility
A systematic review and meta-analysis of randomized controlled trials found that CoQ10 supplementation had significant beneficial effects on sperm quality parameters, with improvements in sperm concentration, motility, and morphology documented across multiple RCTs. Seminal oxidative stress is one of the most consistently identified causes of male factor infertility and elevated sperm DNA fragmentation, and CoQ10 addresses this through the same mitochondrial antioxidant mechanism operative in oocytes. nih
This means CoQ10 is relevant for both partners – an important clinical point that is often missed when the conversation focuses exclusively on egg quality.
Ubiquinone vs. Ubiquinol: The Form Matters
CoQ10 exists in two forms that are frequently conflated in supplement marketing:
Ubiquinone
Ubiquinone is the oxidized form – the form found in most cheaper CoQ10 supplements. It must be reduced to ubiquinol in the body before it can function as an antioxidant in the mitochondrial membrane. This conversion is enzymatic and declines with age.
Ubiquinol
Ubiquinol is the reduced, active antioxidant form – the form that is directly incorporated into the mitochondrial electron transport chain and that functions as the primary membrane-bound antioxidant. It does not require conversion and has substantially better bioavailability than ubiquinone, particularly in older adults.
A pharmacokinetic comparison study found that ubiquinol produced significantly higher plasma CoQ10 concentrations than an equivalent dose of ubiquinone, with the advantage more pronounced in older individuals whose conversion capacity is reduced.3
For women over 35 and for any patient specifically supplementing for egg quality or mitochondrial function, ubiquinol is the appropriate form. For younger women who are supplementing preventively and have good enzymatic conversion capacity, ubiquinone at adequate doses is a reasonable and more economical option – but the dose needs to be sufficient (see below).
CoQ10 Dose: What “Adequate” Actually Means
Dosing in the fertility literature varies across studies, but the most commonly used and clinically validated ranges are:
Women under 35 supplementing preventively or with mild diminished ovarian reserve:
Dose: 200–400 mg/day of ubiquinol, or 400–600 mg/day of ubiquinone
Women 35–40 with diminished ovarian reserve or poor IVF response:
Dose: 400–600 mg/day of ubiquinol
Women over 40 or with significantly diminished ovarian reserve:
Dose: 600 mg/day of ubiquinol; some protocols use up to 800 mg/day
Male partners for sperm DNA fragmentation:
Dose: 200–400 mg/day of ubiquinol or ubiquinone
The 60-day pretreatment period used in the Xu et al. (2018) RCT is the minimum studied; the three-month preparation window I use clinically reflects the full oocyte maturation cycle. Eggs that ovulate in a given cycle begin their maturation approximately 90 days earlier. CoQ10 supplementation started the week before retrieval does not meaningfully influence the eggs being collected.
Coenzyme Q10 is fat-soluble: it must be taken with a fat-containing meal to ensure adequate absorption. Taking it on an empty stomach substantially reduces bioavailability regardless of the form used.
Who Is Most Likely to Benefit From Taking CoQ10
Women over 35: Age-related decline in endogenous CoQ10 production and mitochondrial efficiency makes supplementation directly mechanistically relevant. The evidence base is strongest in this group.
Women with diminished ovarian reserve or low AMH: Poor ovarian response to IVF stimulation is often driven by mitochondrial insufficiency in remaining follicles rather than simply by follicle number. CoQ10 addresses the quality of what remains.
Women with a history of poor IVF response: Multiple cancelled or low-yield cycles, poor fertilization rates, or early embryo arrest are all consistent with inadequate mitochondrial energy in oocytes. A minimum three-month CoQ10 pretreatment before the next cycle is a reasonable and evidence-supported intervention.
Women with PCOS: Elevated follicular oxidative stress in PCOS impairs oocyte maturation independently of the hormonal drivers. CoQ10 addresses this directly.
Women with recurrent miscarriage: Chromosomal abnormalities in embryos – the most common cause of miscarriage – are frequently driven by meiotic spindle errors from mitochondrial energy insufficiency. Reducing the rate of aneuploidy through mitochondrial support is a mechanistically sound approach to miscarriage prevention.
Male partners with elevated sperm DNA fragmentation: Oxidative stress in the epididymis is the most common cause of elevated DFI. CoQ10’s antioxidant effects in mitochondria are relevant to both sperm motility and DNA integrity.
Anyone preparing for IVF or IUI: Optimizing mitochondrial function in the preparation window before a cycle gives the retrieved eggs – however many there are – the best possible developmental competence.
What CoQ10 Cannot Do
This section is as important as everything above.
CoQ10 cannot increase the number of eggs you have. Ovarian reserve – the quantity of remaining primordial follicles – is determined by the depletion rate of follicles over time. CoQ10 does not slow atresia or create new follicles. It optimizes the quality and mitochondrial function of the follicles that are present.
CoQ10 cannot guarantee chromosomally normal eggs. Meiotic errors in aging oocytes have multiple causes beyond mitochondrial insufficiency; CoQ10 reduces one significant contributor but does not eliminate aneuploidy risk.
CoQ10 cannot substitute for medical investigation of poor IVF outcomes. If you have had multiple failed cycles, poor fertilization, or recurrent miscarriage, CoQ10 is an appropriate component of the preparation protocol – but the clinical priority is identifying whether there are other treatable causes (antiphospholipid antibodies, thyroid autoimmunity, sperm DNA fragmentation, endometrial pathology) that require specific intervention.
CoQ10 does not work immediately. Three months is the minimum meaningful preparation window. Results in a single cycle started concurrently with supplementation reflect the eggs that were already in maturation before CoQ10 was started.
CoQ10 in the Context of a Complete Egg Quality Protocol
CoQ10 is the most evidence-supported single intervention for oocyte mitochondrial function, but it works best as part of a coordinated antioxidant and nutritional protocol rather than in isolation:
Melatonin (1-3 mg at bedtime):
Primary antioxidant in follicular fluid; complements CoQ10’s mitochondrial protection with extracellular and membrane-level antioxidant defence. Melatonin levels in follicular fluid decline with age in parallel with CoQ10.
Vitamin E (mixed tocopherols):
Membrane-bound antioxidant that protects oocyte lipid membranes from peroxidation; also independently improves uterine blood flow.
Vitamin C:
Water-soluble antioxidant synergistic with vitamin E; supports collagen synthesis relevant to follicular wall integrity.
N-Acetylcysteine (NAC):
Glutathione precursor; supports the intracellular antioxidant pool that CoQ10 and melatonin protect at the membrane and mitochondrial level.
Vitamin D:
Granulosa cell function, FSH receptor sensitivity, and endometrial receptivity – all relevant to the follicular environment within which CoQ10 is operating.
Alpha-lipoic acid:
Fat- and water-soluble antioxidant that regenerates other antioxidants, including CoQ10 and glutathione; crosses mitochondrial membranes.
The combination produces complementary antioxidant coverage across the different compartments of the developing follicle: the mitochondrial membrane (CoQ10, alpha-lipoic acid), the follicular fluid (melatonin, vitamin C), and the oocyte cell membrane (vitamin E, NAC-derived glutathione).
Specific combinations and doses should be based on your test results, history, and what your cycle timeline allows – a generic protocol applied uniformly is rarely optimal.
Practical Summary
- Use ubiquinol if you are over 35 or specifically targeting egg quality
- Take it with a fat-containing meal – absorption is negligible without dietary fat
- 400–600 mg/day is the clinically validated range for egg quality in women with diminished ovarian reserve; adjust dose with age and severity
- Start three months before a planned retrieval, IUI, or natural conception attempt
- Both partners benefit – CoQ10 reduces sperm DNA fragmentation through the same oxidative stress mechanism operative in oocytes
- Continue through stimulation – CoQ10 is generally safe to continue through IVF stimulation, though the specific protocol should be reviewed with your naturopathic doctor before the stimulation cycle begins
CoQ10 Research References
- May-Panloup P, et al. Mitochondria and their role in oocyte quality. Curr Top Dev Biol. 2016;120:107–141. PMID: 27475848
- Ben-Meir A, et al. Coenzyme Q10 restores oocyte mitochondrial function and fertility during reproductive aging. Aging Cell. 2015;14(5):887–895. PMID: 26132320
- Hosoe K, et al. Study on safety and bioavailability of ubiquinol after single and 4-week multiple oral administration. Regul Toxicol Pharmacol. 2007;47(1):19–28. PMID: 17052808
- Xu Y, et al. Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial. Reprod Biol Endocrinol. 2018;16(1):29. PMID: 29587861
- Giannubilo SR, et al. CoQ10 supplementation in patients undergoing IVF. Nutrients. 2018;10(11):1565. PMID: 30373326
- Turi A, et al. Relationship between coenzyme Q10 concentration in follicular fluid and oocyte quality. Mol Reprod Dev. 2012;79(2):119–126. PMID: 22162239
- Bentov Y, et al. The use of mitochondrial nutrients to improve the outcome of infertility treatment in older patients. Fertil Steril. 2010;93(1):272–275. PMID: 19409550
- Lafuente R, et al. Coenzyme Q10 and male infertility: a meta-analysis. J Assist Reprod Genet. 2013;30(9):1147–1156. PMID: 23912751
